Wednesday, December 2, 2015
Wedbush Reiterates Outperform; $30 Price Target
Wedbush Reiterates Outperform Rating, $30 Price Target on Sangamo as Co. 'Cleared to Initiate In-Vivo Human Testing of its ZFN Based Protein Replacement Platform'
Read more: http://www.benzinga.com/analyst-ratings/analyst-color/15/12/6014924/wedbush-reiterates-outperform-rating-30-price-target-on-#ixzz3tAHvkvIy
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment